Skip to content

A Phase 1/2, Open-Label, Multicenter Trial with a Single Ascending Dose Cohort with Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy of DB-OTO in Children and Infants with Biallelic hOTOF Mutations

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511342-40-00
Acronym
DB-OTO-001
Enrollment
15
Registered
2024-07-02
Start date
2024-03-04
Completion date
Unknown
Last updated
2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

Brief summary

Incidence and severity of treatment-emergent adverse events, Achievement of a hearing sensitivity threshold of ≤70 dB assessed by average pure tone audiometry (PTA)

Detailed description

Auditory Brainstem Response (ABR) to click, Achievement of a hearing sensitivity threshold of ≤45 dB assessed by average PTA, Achievement of hearing sensitivity threshold of ≤25 dB assessed by average PTA, Speech perception scores by age-appropriate tests, Speech Awareness Threshold (SAT): achievement of a threshold of ≤70 dB, SAT: achievement of a threshold of ≤45 dB, SAT: achievement of threshold of ≤25 dB, Speech Reception Threshold (SRT): achievement of a threshold of ≤70 dB, SRT: achievement of a threshold of ≤45 dB, SRT: achievement of a threshold of ≤25 dB, Severity in speech perception ability assessed by Global Impression scales, determined by clinician, Severity in speech perception ability assessed by Global Impression scales, determined by parent/legal guardian, Change in speech perception ability assessed by Global Impression scales, determined by clinician, Change in speech perception ability assessed by Global Impression scales, determined by parent/legal guardian, Average PTA threshold in the subset of patients who achieved an average PTA threshold ≤70 dB, Average PTA threshold in the subset of patients who achieved an average PTA threshold >70 dB but ≤85 dB, Achievement of a hearing sensitivity threshold improvement of ≥10 dB from baseline, Time to an average PTA threshold ≤70 dB, Incidence of patients who regress to >70 dB after having achieved average PTA threshold ≤70 dB, Persistence of an average PTA threshold ≤70 dB

Interventions

DRUGDB-OTO

Sponsors

Regeneron Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Incidence and severity of treatment-emergent adverse events, Achievement of a hearing sensitivity threshold of ≤70 dB assessed by average pure tone audiometry (PTA)

Secondary

MeasureTime frame
Auditory Brainstem Response (ABR) to click, Achievement of a hearing sensitivity threshold of ≤45 dB assessed by average PTA, Achievement of hearing sensitivity threshold of ≤25 dB assessed by average PTA, Speech perception scores by age-appropriate tests, Speech Awareness Threshold (SAT): achievement of a threshold of ≤70 dB, SAT: achievement of a threshold of ≤45 dB, SAT: achievement of threshold of ≤25 dB, Speech Reception Threshold (SRT): achievement of a threshold of ≤70 dB, SRT: achievement of a threshold of ≤45 dB, SRT: achievement of a threshold of ≤25 dB, Severity in speech perception ability assessed by Global Impression scales, determined by clinician, Severity in speech perception ability assessed by Global Impression scales, determined by parent/legal guardian, Change in speech perception ability assessed by Global Impression scales, determined by clinician, Change in speech perception ability assessed by Global Impression scales, determined by parent/legal guardian, Avera

Countries

Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026